Charcot-Marie-Tooth disease tends to go unnoticed for several years before it is confirmed as a diagnosis. Read more at ...

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD Pharma’s oral lead development ...

Charcot-Marie-Tooth (CMT) disease, a group of heritable disorders that affect the peripheral nerves, is marked by specific genetic changes. Research by the team of Prof. Ludo Van Den Bosch (VIB-KU ...

CKD-510 is under development for the treatment of Charcot-Marie-Tooth disease and atrial fibrillation. It is administered through oral route.The drug candidate is a new chemical entity targeting ...

Icerguastat is under clinical development by InFlectis BioScience and currently in Phase I for Charcot-Marie-Tooth Disease Type I B.

A woman in Georgia has filed a police report after an online scammer claiming to be Alan Jackson swindled her out of nearly ...

The research into the function of HDAC6 has also led to opportunities to use CKD-510 in other contexts, including the application to neurodegenerative diseases such as Charcot-Marie-Tooth disease ...

NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd ...

US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...

“I’m tired of broken promises.” Jameson has a genetic disorder called CMT, Charcot-Marie-Tooth disease, that’s largely confining him to a wheelchair. His family has been fighting for City ...